Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 2/20 | 0.45 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.45 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.45 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.45 |
| ▸ | AEBP2 | Q6ZN18 | 2/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21813545 | 1.00 | EED (0.45) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL30845409 | 1.00 | EED (0.45) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL30844980 | 0.91 | UGT8 (0.42) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL21862149 | 0.91 | UGT8 (0.42) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL21813335 | 0.88 | EED (0.50) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL21813815 | 0.81 | UGT8 (0.42) | KDM4E | |
| SCHEMBL21813767 | 0.81 | UGT8 (0.42) | KDM4E | |
| SCHEMBL21813813 | 0.81 | UGT8 (0.42) | KDM4E | |
| SCHEMBL30845110 | 0.81 | UGT8 (0.48) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL21813658 | 0.79 | EED (0.39) | EEDRBBP4SUZ12EZH2AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | EED 1108/4885RBBP4 3426/4885SUZ12 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.